It is essential for clinicians to remain informed about emerging clinical trial opportunities and resulting data that may inform therapeutic strategies, affect clinical guidelines, expand treatment options, and ultimately improve patient quality of life.
Today, we’re showcasing currently active and recently completed U.S.-based clinical trials related to gastroparesis. The following trials are all Phase 2 or Phase 3 trials based in the United States that completed during this year or last year, or are currently active. Trials are arranged by start date.
Quick View Table of Featured Trials
| Study Title | Phase | Recruiting? | Enrollment | Start Date | Primary Completion Date |
|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis. | 2 | No | 416 | January 2025 | May 2026 |
| A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis | 2 | No | 382 | March 2023 | November 2025 |
| Different Doses of Naronapride vs. Placebo in Gastroparesis (MOVE-IT) | 2 | No | 328 | January 2023 | August 2025 |
| Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis | 3 | No | 992 | August 2019 | February 2025 |
| Domperidone in Treating Patients With Gastrointestinal Disorders | 3 | Yes | 200 (estimated) | October 2012 | October 2027 (anticipated) |
Featured Gastroparesis Clinical Trials
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adult Subjects With Idiopathic Gastroparesis
- Sponsor: CinDome Pharma
- Goal: The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects.
- Interventions: CIN-102 Dose 15mg, placebo, CIN-102 dose 10mg
- Primary Outcome Measure: The effect of CIN-102 to significantly decrease nausea severity as compared to baseline based on the average ANMS GCSI-DD nausea subscale score.
- Time Frame: Over the last 2 weeks of the 12-week Treatment Period as compared to baseline.
- Study Details
- Source
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
- Sponsor: CinDome Pharma
- Goal: The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients.
- Interventions: CIN-102 dose 15mg or 10mg
- Primary Outcome Measure: Effect of CIN-102 to significantly decrease gastroparesis-related symptoms as compared to baseline based on the composite of the average ANMS GCSI-DD nausea sub-scale and vomiting scores.
- Time Frame: Over the last 2 weeks of the 12-week treatment period as compared to baseline.
- Study Details
- Source
Different Doses of Naronapride vs. Placebo in Gastroparesis (MOVE-IT)
- Sponsor: Dr. Falk Pharma GmbH
- Goal: The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to compare oral treatment with daily doses of 10, 20, or 40 mg naronapride vs. placebo for the treatment of patients with gastroparesis.
- Interventions: Naronapride, placebo
- Primary Outcome Measure: Change in the American Neurogastroenterology and Motility Society Gastroparesis Cardinal Symptom Index - Daily Diary total score from baseline to week 12.
- Time Frame: 12 weeks.
- Study Details
- Source
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
- Sponsor: Vanda Pharmaceuticals
- Goal: To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.
- Interventions: Tradipitant, placebo, open label tradipitant
- Primary Outcome Measure: Change from baseline in daily average nausea severity scores from the Gastroparesis Core Symptom Daily Diary (GCS-DD).
- Time Frame: 12 weeks.
- Study Details
- Source
Domperidone in Treating Patients With Gastrointestinal Disorders
- Sponsor: M.D. Anderson Cancer Center
- Goal: This phase III trial studies how well domperidone works in treating patients with gastrointestinal disorders.
- Interventions: Doperidone, questionnaire administration
- Primary Outcome Measure: Attenuation of symptoms associated with disorder(s) of gastrointestinal motility, measured by change in Gastroparesis Cardinal Symptom Index (GSCI) score from baseline.
- Time Frame: Baseline to eight weeks.
- Study Details
- Source
Related Guidelines:
- Management of Gastroparesis
- American Gastroenterological Association
- September 2025
- Gastroparesis
- American College of Gastroenterology
- August 2022
Check out our other gastroenterology content and sign up for alerts and stay informed on the latest published guidelines.